Search Results

The Leukemia & Lymphoma Society's Response to the Israel-Hamas War

The following message was sent to all LLS employees on October , : Dear LLS Community,   As an organization, The Leukemia & Lymphoma Society (LLS) is …

The Leukemia & Lymphoma Society Receives Grant Award from Disabled Veterans National Foundation

Rye Brook, NY- July , – The Leukemia & Lymphoma Society (LLS) is honored to announce it has received a grant from the Disabled Veterans National Foun…

The Leukemia & Lymphoma Society Receives $17 Million from the Mike and Sofia Segal Family Foundation to Accelerate Progress in the Treatment of Chronic Myelomonocytic Leukemia

Mike and Sofia Segal, who immigrated to the U.S. from Ukraine in , lead foundation that supports overlooked and underfunded causes, including rare di…

The Leukemia & Lymphoma Society (LLS) Data at ASH Provides Glimpse into the Future of Blood Cancer Treatment

New data from LLS master clinical trials — Beat AML® and Pediatric Acute Leukemia (PedAL) — show promise for leukemias Leaders available to provide …

The Leukemia & Lymphoma Society (LLS) Data and Presence at ASH Showcase Latest Blood Cancer Treatment Breakthroughs

Numerous researchers and Therapy Acceleration Program (TAP) partners will present data on the most recent developments in blood cancer.LLS’s scientif…

FDA Approves New Drug to Treat a Serious Immune Condition that Can Affect Children with Blood Cancer

Ryoncil® is for children months and older who get acute disease () after a stem cell transplant Rye Brook, N.Y., January , – The U.S. Food and Dru…

The Leukemia & Lymphoma Society Denounces Federal Actions that Threaten Cancer Patients

WASHINGTON, February , – As the nation’s largest organization serving the critical needs of blood cancer patients, we are alarmed by recent actions t…

The Leukemia & Lymphoma Society Announces Reimagined Executive Leadership Team

See full multimedia release here.

The Leukemia & Lymphoma Society 2025 Research Grants Include Acute Leukemia in Children with Down Syndrome

LLS has more than $ million research funding commitments to propel the next generation of blood cancer care Patient education, financial support and a…

Latest FDA Approval in Multiple Myeloma May Reduce Treatment Costs, Frequency and Side Effects

The FDA’s approval of a less frequent treatment regimen in patients with multiple myeloma highlights a trend of making treatments easier for blood can…

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

SAN DIEGO, December , – Kura Oncology, Inc. (NASDAQ: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines fo…

Global Partnership to Fund Groundbreaking Research in Treatment of Multiple Myeloma

Groundbreaking research aimed at translating novel chimeric antigen receptor (CAR) therapies into improved treatment for multiple myeloma is the late…

First 2025 New Blood Cancer Drug Approval Adds Years of Life for People Living with Mantle Cell Lymphoma

Mantle cell is an aggressive form of lymphoma Rye Brook, N.Y., January , – Acalabrutinib (Calquence®) is the first ever drug of its type approved f…

FDA’s Recent Approval of 2 CAR T-Cell Therapies a ‘Big Step Toward’ Long-Term Control of Myeloma for More Patients

The FDA has approved (Carvykti™) and (Abecma®) for earlier treatment of multiple myeloma.Rye Brook, N.Y., April , – The U.S. Food and Drug Administ…

FDA’s ODAC Endorses New Indications for 2 CAR-T Therapies for Myeloma

Rye Brook, N.Y., March , – Today’s vote by the FDA’s Oncologic Drugs Advisory Committe (ODAC), a group of independent cancer experts, stating that th…

FDA Expands Use of Leukemia Treatment to Include Children

LLS supported the very first conjugate gemtuzumab ozogamicin, which targets CD33, and was approved in to treat acute myeloid leukemia.

FDA Approves Treatment for Myelofibrosis and Anemia

Rye Brook, N.Y., September , – The U.S. Food and Drug Administration (FDA) recently approved momelotinib (Ojjaara™) for use in adults with intermedia…

FDA Approves Targeted Therapy for Patients with Newly Diagnosed Multiple Myeloma

LLS was an early funder of research that identified the CD38 protein as a target for blood cancer treatment Rye Brook, N.Y., October ,  – The U.S. Fo…

FDA Approves Targeted Immunotherapy for Aggressive Forms of Follicular Lymphoma

Epcoritamab works by engaging the immune system to kill cancer cells Rye Brook, N.Y., June ,  – The U.S. Food and Drug Administration (FDA) on Wednesd…

FDA Approves New Treatment for Adults with Chronic Myeloid Leukemia

Asciminib provides another option to help CML patients live longer, healthier lives Rye Brook, N.Y., December , – The U.S. Food and Drug Administrati…

FDA Approves a New Immune-Based Treatment Option for People with Mantle Cell Lymphoma

The FDA continues to expand availability of breakthrough CAR immunotherapy to benefit more blood cancer patientsRye Brook, N.Y., May , – The U.S. Fo…

Resource Hub - Patient Resources Page (version 2)

Example Question Guides for Blood Cancer Patients

Before you visit your doctor and other healthcare providers, it's a good idea to write down your questions or concerns. For a list of suggested questi…

Blood Cancer United DIY fundraising FAQ

Here's what you need to know about Blood Cancer United DIY fundraising. See how you can use our fundraising platforms to make it easy to start your ow…

Accessibility Statement

Blood Cancer United (BCU) is committed to ensuring that all users have equal access to its products and services, including through an accessible webs…